SAN DIEGO--(BUSINESS WIRE)-- Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies and advanced science to find new solutions for devastating cancers and immune disorders, has been recognized as a Top Workplaces 2022 award winner by the San Diego Union-Tribune. The annual competition involves San Diego area companies of all sizes and industries. Awards are based on rankings from anonymous company-wide employee surveys that measure culture drivers critical to the success of any organization such as: engagement, strategic direction, inclusion, transparency, cooperation, and support for personal growth.

“Being recognized as a Top Workplaces 2022 company is a significant honor for Vividion,” said Jeffrey Hatfield, chief executive officer of Vividion. “It’s especially gratifying to earn the #2 mid-size company ranking, given the large number of high-quality area companies competing. The fact that these results are driven by direct feedback from our employees about their personal experience working here means so much. We’re a high-growth biotech company making real progress on unlocking new solutions for patients suffering from devastating diseases like cancer. The amazing scientific and operational team members here are our most valuable resource in pursuing that mission, and we will continue our strong commitment to having a ‘Top Workplace’ environment that supports them. This is a proud moment, and we thank both the Union-Tribune and Energage for leading this award process.”

In addition, Mr. Hatfield was recognized as the overall 2022 Leadership Award honoree among all midsize companies within the 2022 competition.

About Vividion

Vividion Therapeutics, Inc. a wholly owned and independently operated subsidiary of Bayer AG acquired in August 2021, is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses, before special items, amounted to 5.3 billion euros. For more information, go to www.bayer.com.

About Energage

Making the world a better place to work together.^TM

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 16 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com.

Find more information at https://pharma.bayer.com/

Follow us on Facebook: http://www.facebook.com/bayer

Follow us on Twitter: @BayerPharma

Vividion Therapeutics, Inc. is a biopharmaceutical company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a deep and diversified pipeline of highly selective small molecule therapeutics targeting high value disease-causing proteins in oncology and immunology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005255/en/